BrainStorm Cell Therapeutics is a biotechnology company engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases including: Amyotrophic Lateral Sclerosis; Progressive Multiple Sclerosis; Alzheimer's disease; and other neurodegenerative diseases. NurOwn®, Co.'s proprietary cell therapy platform, utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. We show 41 historical shares outstanding datapoints in our BCLI shares outstanding history coverage, used to compute BCLI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BCLI market cap history over the course of time is important for investors
interested in comparing BCLI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BCLI versus a peer is one thing; comparing
BCLI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BCLI can fluctuate over the course of history.
With this page we aim to empower investors researching BCLI by allowing them to research the BCLI market cap history. |
Free BCLI Email Alerts:
Video: The Importance of Market Cap
